ARTICLE | Company News
Icos, Biogen in LFA-1 deal
July 16, 2001 7:00 AM UTC
The companies will jointly develop and market orally active LFA-1 antagonists, including ICOS's IC747, for the treatment of inflammatory and autoimmune conditions. The companies will cross-license LFA...